AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A pharmaceutical composition for treatment of cancer disease comprising an antibody directed against the cellular membrane antigen Ep-CAM and at least one adjuvant useful in the formulation of a vaccine to thereby enhance an immune response, wherein said antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO: 1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO: 2.

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Previously Presented) The pharmaceutical composition of claim 1, wherein said first antibody is contained in a dosage range of 0.01 – 4 mg.

8. (Previously Presented) A method of treating cancer disease comprising administering to a patient in need thereof the pharmaceutical composition of claim 1.

9. (Previously Presented) The method according to claim 8, wherein said pharmaceutical composition is administered by subcutaneous, intradermal or intramuscular injection.

10. (Canceled)

11. (Cancelled)

12. (Previously Presented) The method of claim 8 or 9 wherein said antibody is administered at a dosage in the range of 0.01 to 4 mg antibody.

13. (Canceled)

14. (Previously Presented) The method according to claim 12 wherein said dosage is 0.5 mg antibody.

15. (New) The pharmaceutical composition of claim 1, wherein said adjuvant is at least one member selected from the group consisting of aluminum hydroxide, a lipopolysaccharide derivative, a Bacillus Calmette Guerin liposome preparation, tetanus toxoid, pseudommas exotoxin, an influenza virus, GM-CSF, IL-2 or IFN8.

16. (New) The pharmaceutical composition of claim 1, further comprising at least one second antibody directed against a different membrane antigen or against a different epitope of said Ep-CAM membrane antigen.

17. (New) An individual dosage vaccine formulation which comprises 0.01 – 4 mg of an antibody directed against the cellular membrane antigen Ep-CAM and at least one adjuvant useful in the formulation of a vaccine to thereby enhance an immune response, wherein said antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO: 1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO: 2.

18. (New) The formulation of claim 17, wherein said adjuvant is at least one member selected from the group consisting of aluminum hydroxide, a lipopolysaccharide derivative, a Bacillus Calmette Guerin liposome preparation, tetanus toxoid, pseudommas exotoxin, an influenza virus, GM-CSF, IL-2 or IFN8.

19. (New) The formulation of claim 17, further comprising at least one second antibody directed against a different membrane antigen or against a different epitope of said Ep-CAM membrane antigen.

20. (New) A method of treating cancer disease which comprises administering an effective cancer treatment amount in the range of 0.01–4 mg of a first antibody directed against the cellular membrane antigen Ep-CAM, wherein said antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO: 1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO: 2.

21. (New) The method of claim 20, wherein said first antibody is administered in an amount of 0.01–4 mg.

22. (New) The method of claim 21, wherein said first antibody is administered in combination with at least one adjuvant useful in the formulation of a vaccine.

23. (New) The method of claim 22, wherein said adjuvant is at lest one member selected from the group consisting of aluminum hydroxide, a lipopolysaccharide derivative, a Bacillus Calmette Guerin liposome preparation, tetanus toxoid, Pseudomonas exotoxin, an influenza virus, GM-CSF, IL-2 or IFN8.

24. (New) The method according to claim 21, wherein said first antibody is administered in combination with at least one second antibody directed against a different membrane antigen or against a different epitope of said Ep-CAM membrane antigen.